Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.
The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use.
The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said.
In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease.
North Macedonia elections: What is at stake? Who are contesting? All you need to know
Chinese scientists invent ultrathin optical crystal for next
In new movie, the South started the Korean War, as Pyongyang has always claimed — Radio Free Asia
Xi highlights advancement in education
Judge delays murder trial for Indiana man charged in 2017 slayings of 2 teenage girls
Chinese police take back 130 gambling, scam suspects from Cambodia
Former chairman of China Everbright Group indicted for embezzlement, bribery
Multiple glass materials discovered in Chang'e
Wisconsin wedding barns sue over state's new liquor law requiring licensing
Guideline cleans up pollutants
Oklahoma State hires Olympic gold medalist David Taylor as wrestling coach
SpaceX launches 23 more Starlink internet satellites into space